Depomed (NASDAQ:DEPO) Earning Somewhat Favorable News Coverage, Accern Reports
Media headlines about Depomed (NASDAQ:DEPO) have trended somewhat positive recently, Accern Sentiment reports. The research firm identifies positive and negative news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Depomed earned a news sentiment score of 0.15 on Accern’s scale. Accern also gave news headlines about the specialty pharmaceutical company an impact score of 45.5157910133985 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
These are some of the headlines that may have effected Accern Sentiment Analysis’s rankings:
- Edited Transcript of DEPO earnings conference call or presentation 7-Aug-17 8:30pm GMT (finance.yahoo.com)
- Depomed, Inc. – Value Analysis (NASDAQ:DEPO) : August 11, 2017 (finance.yahoo.com)
- IHS Markit Score Update: Drop in demand for ETFs holding Depomed Inc is a negative sign for its shares (finance.yahoo.com)
- Depomed, Inc. (NASDAQ:DEPO) Stock Rating Reaffirmed by Piper Jaffray Companies (americanbankingnews.com)
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Depomed, Inc. – DEPO – PR Newswire (press release) (prnewswire.com)
A number of brokerages have commented on DEPO. Janney Montgomery Scott cut Depomed from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $18.00 to $8.00 in a research note on Tuesday, August 8th. Royal Bank Of Canada reduced their price objective on Depomed from $13.00 to $10.00 and set a “sector perform” rating on the stock in a research note on Tuesday, August 8th. BidaskClub cut Depomed from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 5th. Morgan Stanley cut Depomed from an “equal weight” rating to an “underweight” rating and cut their price target for the stock from $12.00 to $5.00 in a research note on Tuesday, August 8th. Finally, Piper Jaffray Companies reiterated a “neutral” rating and issued a $9.00 price target (down previously from $10.00) on shares of Depomed in a research note on Wednesday. Four equities research analysts have rated the stock with a sell rating, six have given a hold rating and three have given a buy rating to the company. Depomed presently has an average rating of “Hold” and a consensus price target of $14.59.
Depomed (DEPO) traded up 0.96% on Friday, hitting $6.32. The company had a trading volume of 1,585,296 shares. Depomed has a 12-month low of $5.95 and a 12-month high of $27.02. The firm’s 50 day moving average price is $10.06 and its 200 day moving average price is $12.61. The stock’s market cap is $398.08 million.
Depomed (NASDAQ:DEPO) last released its quarterly earnings results on Monday, August 7th. The specialty pharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.09 by $0.52. Depomed had a negative net margin of 26.02% and a negative return on equity of 45.03%. The firm had revenue of $100 million for the quarter, compared to the consensus estimate of $100.40 million. During the same quarter last year, the company earned $0.27 earnings per share. The firm’s revenue was down 14.3% on a year-over-year basis. Equities analysts predict that Depomed will post $0.51 earnings per share for the current fiscal year.
In other news, insider Arthur J. Higgins purchased 15,000 shares of the firm’s stock in a transaction on Monday, June 12th. The stock was bought at an average cost of $9.92 per share, for a total transaction of $148,800.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 2.59% of the stock is owned by corporate insiders.
TRADEMARK VIOLATION NOTICE: “Depomed (NASDAQ:DEPO) Earning Somewhat Favorable News Coverage, Accern Reports” was posted by Daily Political and is the sole property of of Daily Political. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be read at https://www.dailypolitical.com/2017/08/13/depomed-nasdaqdepo-earning-somewhat-favorable-news-coverage-accern-reports.html.
Depomed, Inc is a specialty pharmaceutical company. The Company focuses on pain and other central nervous system (CNS) conditions. Its products include NUCYNTA ER (tapentadol extended release tablets), NUCYNTA IR (NUCYNTA) (tapentadol), Gralise (gabapentin), CAMBIA (diclofenac potassium for oral solution), Zipsor (diclofenac potassium) and Lazanda (fentanyl).
Receive News & Ratings for Depomed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Depomed Inc. and related companies with MarketBeat.com's FREE daily email newsletter.